ReviewWorld journal of gastroenterology2012
Changes of the cytokine profile in inflammatory bowel diseases.
Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04733456 (Evaluation of Brain Activity and Oxygenation Using Near-infrared Spectroscopy), which is not on this map. Cited by 129 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Brain Activity and Oxygenation Using Near-infrared Spectroscopy (NIRS) in Inflammatory Bowel Disease (IBD) Patients
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it, 249 citations in OpenAlex.
- The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.Journal of clinical pharmacology · 2016Trial
- A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.British journal of clinical pharmacology · 2015Trial
- Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Pimenta racemosa extract ameliorates chemically induced ulcerative colitis in rats by suppressing inflammation and oxidative stress.Inflammopharmacology · 2026Article
- Preventive Effects of Probiotic and PostbioticJournal of microbiology and biotechnology · 2026Article
- Pathophysiological Links Between Inflammatory Bowel Disease and Cardiovascular Disease: The Role of Dysbiosis and Emerging Biomarkers.Biomedicines · 2025Review
- LivemBio · 2025Article
- The Mechanistic Target of Rapamycin MediatesMicroorganisms · 2025Article
- C9orf72 Alleviates DSS‑Induced Ulcerative Colitis via the cGAS-STING Pathway.Immunity, inflammation and disease · 2025Article
- Probiotic bacteria vs. yeast for gastrointestinal diseases treatment: Protocol for a systematic review and meta-analysis.PloS one · 2025Article
- Protective effects ofFrontiers in immunology · 2025Article
- In Vitro Protective Effects of a Standardized Extract ofAntioxidants (Basel, Switzerland) · 2024Article
- Zhumeria majdae essential oil attenuates TNBS-induced colitis in rats by regulating inflammatory and apoptotic pathways.Inflammopharmacology · 2024Article
- 2'-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT3.Inflammatory bowel diseases · 2024Article
- Identification of plasma and urinary inflammatory markers in severe knee osteoarthritis: Relations with synovial fluid markers.Knee surgery & related research · 2024Article
- Crosstalk Between Microbiota, Microbial Metabolites, and Interferons in the Inflammatory Bowel Disease Gut.Journal of the Canadian Association of Gastroenterology · 2024Review
- In vitro co-culture models for studying organoids-macrophages interaction: the golden technology of cancer immunotherapy.American journal of cancer research · 2024Review
- Sturgeon-derived peptide LLLE alleviates colitis via regulating gut microbiota and its metabolites.Current research in food science · 2024Article
- Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines are indispensable signals of the mucosa-associated immune system for maintaining normal gut homeostasis. An imbalance of their profile in favour of inflammation initiation may lead to disease states, such as that is observed in inflammatory bowel diseases (IBD). Although Crohn's disease (CD) is often described as a prototype of T-helper 1-type diseases, and ulcerative colitis (UC) is traditionally viewed as a T-helper 2-mediated condition, the classic paradigm, which categorises cytokines into pro- and anti-inflammatory groups, has recently been changed. The inflammation regulatory pathways may not be mutually exclusive as individual cytokines can have diverse and even opposing functions in various clinical and immunological settings. None the less there are many common immunological responses in IBD that are mediated by cytokines. Although they regulate and influence the development, course and recurrence of the inflammatory process, the concrete pathogenic role of these small signaling molecules is sometimes not unambiguous in the subtypes of the disease. Our aim is to review the current information about pro- and anti-inflammatory effects of traditionally studied and recently discovered cytokines in the pathogenesis of UC and CD. The better understanding of their production and functional activity may lead to the development of new therapeutic modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.